The silent treatment: SiRNAs as small molecule drugs

D. M. Dykxhoorn, D. Palliser, J. Lieberman

Research output: Contribution to journalArticle

283 Citations (Scopus)

Abstract

As soon as RNA interference (RNAi) was found to work in mammalian cells, research quickly focused on harnessing this powerful endogenous and specific mechanism of gene silencing for human therapy. RNAi uses small RNAs, less than 30 nucleotides in length, to suppress expression of genes with complementary sequences. Two strategies can introduce small RNAs into the cytoplasm of cells, where they are active - a drug approach where double-stranded RNAs are administered in complexes designed for intracellular delivery and a gene therapy approach to express precursor RNAs from viral vectors. Phase I clinical studies have already begun to test the therapeutic potential of small RNA drugs that silence disease-related genes by RNAi. This review will discuss progress in developing and testing small RNAi-based drugs and potential obstacles.

Original languageEnglish (US)
Pages (from-to)541-552
Number of pages12
JournalGene Therapy
Volume13
Issue number6
DOIs
StatePublished - Mar 2006
Externally publishedYes

Fingerprint

RNA Interference
RNA
Pharmaceutical Preparations
Double-Stranded RNA
RNA Precursors
Viral RNA
Gene Silencing
Therapeutics
Genetic Therapy
Cytoplasm
Nucleotides
Gene Expression
Research
Genes

Keywords

  • Drug development
  • RNA interference
  • Small interfering RNA
  • Therapy

ASJC Scopus subject areas

  • Genetics

Cite this

Dykxhoorn, D. M., Palliser, D., & Lieberman, J. (2006). The silent treatment: SiRNAs as small molecule drugs. Gene Therapy, 13(6), 541-552. https://doi.org/10.1038/sj.gt.3302703

The silent treatment : SiRNAs as small molecule drugs. / Dykxhoorn, D. M.; Palliser, D.; Lieberman, J.

In: Gene Therapy, Vol. 13, No. 6, 03.2006, p. 541-552.

Research output: Contribution to journalArticle

Dykxhoorn, DM, Palliser, D & Lieberman, J 2006, 'The silent treatment: SiRNAs as small molecule drugs', Gene Therapy, vol. 13, no. 6, pp. 541-552. https://doi.org/10.1038/sj.gt.3302703
Dykxhoorn, D. M. ; Palliser, D. ; Lieberman, J. / The silent treatment : SiRNAs as small molecule drugs. In: Gene Therapy. 2006 ; Vol. 13, No. 6. pp. 541-552.
@article{24cc6b4efc924923bec45345e4d906e8,
title = "The silent treatment: SiRNAs as small molecule drugs",
abstract = "As soon as RNA interference (RNAi) was found to work in mammalian cells, research quickly focused on harnessing this powerful endogenous and specific mechanism of gene silencing for human therapy. RNAi uses small RNAs, less than 30 nucleotides in length, to suppress expression of genes with complementary sequences. Two strategies can introduce small RNAs into the cytoplasm of cells, where they are active - a drug approach where double-stranded RNAs are administered in complexes designed for intracellular delivery and a gene therapy approach to express precursor RNAs from viral vectors. Phase I clinical studies have already begun to test the therapeutic potential of small RNA drugs that silence disease-related genes by RNAi. This review will discuss progress in developing and testing small RNAi-based drugs and potential obstacles.",
keywords = "Drug development, RNA interference, Small interfering RNA, Therapy",
author = "Dykxhoorn, {D. M.} and D. Palliser and J. Lieberman",
year = "2006",
month = "3",
doi = "10.1038/sj.gt.3302703",
language = "English (US)",
volume = "13",
pages = "541--552",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - The silent treatment

T2 - SiRNAs as small molecule drugs

AU - Dykxhoorn, D. M.

AU - Palliser, D.

AU - Lieberman, J.

PY - 2006/3

Y1 - 2006/3

N2 - As soon as RNA interference (RNAi) was found to work in mammalian cells, research quickly focused on harnessing this powerful endogenous and specific mechanism of gene silencing for human therapy. RNAi uses small RNAs, less than 30 nucleotides in length, to suppress expression of genes with complementary sequences. Two strategies can introduce small RNAs into the cytoplasm of cells, where they are active - a drug approach where double-stranded RNAs are administered in complexes designed for intracellular delivery and a gene therapy approach to express precursor RNAs from viral vectors. Phase I clinical studies have already begun to test the therapeutic potential of small RNA drugs that silence disease-related genes by RNAi. This review will discuss progress in developing and testing small RNAi-based drugs and potential obstacles.

AB - As soon as RNA interference (RNAi) was found to work in mammalian cells, research quickly focused on harnessing this powerful endogenous and specific mechanism of gene silencing for human therapy. RNAi uses small RNAs, less than 30 nucleotides in length, to suppress expression of genes with complementary sequences. Two strategies can introduce small RNAs into the cytoplasm of cells, where they are active - a drug approach where double-stranded RNAs are administered in complexes designed for intracellular delivery and a gene therapy approach to express precursor RNAs from viral vectors. Phase I clinical studies have already begun to test the therapeutic potential of small RNA drugs that silence disease-related genes by RNAi. This review will discuss progress in developing and testing small RNAi-based drugs and potential obstacles.

KW - Drug development

KW - RNA interference

KW - Small interfering RNA

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=33645148088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645148088&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3302703

DO - 10.1038/sj.gt.3302703

M3 - Article

C2 - 16397510

AN - SCOPUS:33645148088

VL - 13

SP - 541

EP - 552

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 6

ER -